Gongwin Taiwan signs licensing deals to expand lung cancer drug markets

Biopharmaceutical company Gongwin Taiwan signed two key licensing agreements Wednesday to expand access to its innovative lung cancer drug PTS-302 in Taiwan and Malaysia, according to its parent company Gongwin Biopharm Co. (GBC).

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)